Get the Stockscreener App
0.6914
2.12%
-0.015
Citius Pharmaceuticals Inc stock is traded at $0.6914, with a volume of 74,940.
It is down -2.12% in the last 24 hours and down -9.62% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$0.7064
Open:
$0.7059
24h Volume:
74,940
Relative Volume:
0.27
Market Cap:
$7.11M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.1158
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
-1.65%
1M Performance:
-9.62%
6M Performance:
-79.17%
1Y Performance:
-95.78%
1-Day Range:
$0.67
$0.7195
1-Week Range:
$0.67
$0.738
52-Week Range:
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.6914 | 7.45M | 0 | -39.14M | -28.20M | -5.97 |
|
ONC
Beone Medicines Ltd Adr
|
245.77 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.93 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.40 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Consensus Price Target from Brokerages - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Cut to Hold at Maxim Group - Defense World
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim Group - GuruFocus
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Pharmaceuticals (CTXR) Downgraded to Hold by Maxim | CTXR Stock News - GuruFocus
Citius Pharmaceuticals (NASDAQ:CTXR) Earns Buy Rating from D. Boral Capital - Defense World
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating fr - GuruFocus
Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments - TipRanks
Citius Pharmaceuticals (CTXR) Receives Continued "Buy" Rating from Analyst | CTXR Stock News - GuruFocus
Citius Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financi - GuruFocus
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals (CTXR) to Release Quarterly Earnings on Tuesday - Defense World
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ - Barchart.com
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - The Malaysian Reserve
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares Sold by Geode Capital Management LLC - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.92 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.92 By Investing.com - Investing.com Canada
Citius Pharmaceuticals (CTXR) Price Target Adjusted to $4 Amid S - GuruFocus
Citius Pharmaceuticals stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.94 - Investing.com Australia
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Pharmaceuticals stock plummets on $2M registered direct offering of common stock - MSN
Citius Pharmaceuticals stock hits 52-week low at $1.21 - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $1.21 By Investing.com - Investing.com India
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com Australia
Citius Pharmaceuticals announces $2M registered direct offering of common stock - TipRanks
CTXR’s Stock Woes: Down -87.99% in 6 Months, Down -87.99% in Just 5 Days - investchronicle.com
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
Analysts Expect Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) To Breakeven Soon - simplywall.st
Citius Pharmaceuticals stock hits 52-week low at $1.45 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $1.45 - Investing.com India
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - simplywall.st
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):